Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research
Backgrounder
[ News Release: The Government of Canada invests over $21M in innovative health research ]
Through new CIHR funding, researchers will undertake innovative biomedical and clinical HIV vaccine research projects in new areas of investigation or take previous discoveries in new directions; promote the development and testing of novel HIV vaccine research tools and methodologies; and support high-risk HIV vaccine research projects with the potential for high impact, breakthrough and/or transformative advances.
A total of ten researchers and two new investigators from across the country were awarded $2.9M dollars for the following projects:
| Researcher | Institution | Project Title | Amount |
|---|---|---|---|
| Dr. Petronela Ancuta | Centre hospitalier de l'Université de Montréal (CHUM) | Targeting mTOR to restore mucosal immunity toward remission in HIV-infected individuals | $250,000 |
| Dr. Eric Arts | University of Western Ontario | Developing the ACT-VEC as an HIV therapeutic vaccine and cure approach | $250,000 |
| Dr. Dimitrios Dikeakos | University of Western Ontario | Nef Inhibitors as Adjuvants Towards a Cure | $247,755 |
| Dr. Jérôme Estaquier | Université Laval | Role of follicular CD8 T cells in the control of HIV/SIV mucosal immunity. | $250,000 |
| Dr. Daniel E Kaufmann | Centre hospitalier de l'Université de Montréal (CHUM) | Influence of pre-existing HIV cross-reactive CD4 T cells on vaccine responses to new Env immunogens | $249,994 |
| Dr. Charu Kaushic | McMaster University | Improving vaginal health to decrease biological risk of HIV-1 infection in Canadian ACB women | $250,000 |
| Dr. Denis Leclerc | Université Laval | Adjuvantization of SIV antigens using a novel toll like receptor 7 (TLR7) agonist: A proof of concept in non-human primate. | $250,000 |
| Dr. Lyle R Mckinnon | University of Manitoba | Impact of Vedolizumab on immune cell homing to the female reproductive and gastrointestinal mucosa | $249,460 |
| Dr. Mario A Ostrowski | University of Toronto | Developing a Novel Modular Nanoparticle Vaccine Strategy to Induce Durable Systemic and Mucosal HIV Envelope Specific Antibodies | $250,000 |
| Dr. Jean-Pierre Routy | Research Institute of the McGill University Health Centre | Locking out HIV from CD4 T cells: A pilot study of the impact of anti a4b7 antibody (vedolizumab) on viral control following analytical treatment interruption | $247,650 |
| Adam Burgener | University of Manitoba | Mechanisms of metaproteome factors in HIV infection risk in young women | $249,888 |
| Ruey-Chyi | University of Manitoba | Elucidating the role of cell homing pathways in controlling endothelial cell-mediated enhancement of resting CD4+ T cell infection by HIV | $206,600 |
Page details
- Date modified: